Salvato in:
Dettagli Bibliografici
Autori principali: Zhao, Siqi, Moller, Joshua, Quintero-Cadena, Porfi, van Niekerk, Lood
Natura: Preprint
Pubblicazione: 2025
Soggetti:
Accesso online:https://arxiv.org/abs/2507.02670
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1866915370585030656
author Zhao, Siqi
Moller, Joshua
Quintero-Cadena, Porfi
van Niekerk, Lood
author_facet Zhao, Siqi
Moller, Joshua
Quintero-Cadena, Porfi
van Niekerk, Lood
contents Therapeutic antibodies require not only high-affinity target engagement, but also favorable manufacturability, stability, and safety profiles for clinical effectiveness. These properties are collectively called `developability'. To enable a computational framework for optimizing antibody sequences for favorable developability, we introduce a guided discrete diffusion model trained on natural paired heavy- and light-chain sequences from the Observed Antibody Space (OAS) and quantitative developability measurements for 246 clinical-stage antibodies. To steer generation toward biophysically viable candidates, we integrate a Soft Value-based Decoding in Diffusion (SVDD) Module that biases sampling without compromising naturalness. In unconstrained sampling, our model reproduces global features of both the natural repertoire and approved therapeutics, and under SVDD guidance we achieve significant enrichment in predicted developability scores over unguided baselines. When combined with high-throughput developability assays, this framework enables an iterative, ML-driven pipeline for designing antibodies that satisfy binding and biophysical criteria in tandem.
format Preprint
id arxiv_https___arxiv_org_abs_2507_02670
institution arXiv
publishDate 2025
record_format arxiv
spellingShingle Guided Generation for Developable Antibodies
Zhao, Siqi
Moller, Joshua
Quintero-Cadena, Porfi
van Niekerk, Lood
Machine Learning
Biomolecules
Therapeutic antibodies require not only high-affinity target engagement, but also favorable manufacturability, stability, and safety profiles for clinical effectiveness. These properties are collectively called `developability'. To enable a computational framework for optimizing antibody sequences for favorable developability, we introduce a guided discrete diffusion model trained on natural paired heavy- and light-chain sequences from the Observed Antibody Space (OAS) and quantitative developability measurements for 246 clinical-stage antibodies. To steer generation toward biophysically viable candidates, we integrate a Soft Value-based Decoding in Diffusion (SVDD) Module that biases sampling without compromising naturalness. In unconstrained sampling, our model reproduces global features of both the natural repertoire and approved therapeutics, and under SVDD guidance we achieve significant enrichment in predicted developability scores over unguided baselines. When combined with high-throughput developability assays, this framework enables an iterative, ML-driven pipeline for designing antibodies that satisfy binding and biophysical criteria in tandem.
title Guided Generation for Developable Antibodies
topic Machine Learning
Biomolecules
url https://arxiv.org/abs/2507.02670